secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0000950170-23-053115
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports preclinical Gemini data showing biomarker activity; Phase 1 study planned
--------------------------------------------------------------------------------

- Gemini showed dose-dependent white blood cell mobilization and cytokine upregulation (IL-10, NGAL, IL-6) in healthy animal models.
- Data supports Gemini as a preventative therapy for infection and acute kidney injury; key biomarkers confirmed.
- Company plans to initiate a Phase 1 healthy volunteer study later this year, with full results to be published.
- Second dose of Gemini demonstrated attenuated IL-6 response indicating trained immunity; two-dose regimen being evaluated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023053115/0000950170-23-053115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023053115/revb-20231012.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer